LTFS
ELDN icon

Ladenburg Thalmann Financial Services’s Eledon Pharmaceuticals ELDN Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2
Closed – – 5048
2017
Q3 		$0 Hold
2
– – ﹤0.01% 4947
2017
Q2 		$0 Hold
2
– – ﹤0.01% 4893
2017
Q1 		$0 Hold
2
– – ﹤0.01% 4874
2016
Q4 		$0 Buy
+2
New +$383 ﹤0.01% 4865
2015
Q4 		– Sell
-2
Closed -$3K – 4697
2015
Q3 		$3K Hold
2
– – ﹤0.01% 4133
2015
Q2 		$4K Buy
+2
New +$3.87K ﹤0.01% 4122

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Derby & Company Newton, Massachusetts $495M AUM 23.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ELDN Position: Q4 2017 in Review

Ladenburg Thalmann Financial Services sold out of Eledon Pharmaceuticals (ELDN) in Q4 2017, closing a stake of 2 shares.

Ladenburg Thalmann Financial Services first reported a position in ELDN in Q2 2015 and held it in 6 quarters. The position peaked at $4K in Q2 2015. 11 funds tracked by Wall St. Rank hold ELDN as of Q4 2017.

  • Ladenburg Thalmann Financial Services reported no remaining Eledon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 2 Eledon Pharmaceuticals shares in Q4 2017.
  • Ladenburg Thalmann Financial Services first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Ladenburg Thalmann Financial Services's Eledon Pharmaceuticals position peaked at $4K in Q2 2015.
  • 11 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2017.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2017, filed 14 Feb 2018.